You are here: Home » Companies » News
Business Standard

Ranbaxy gets US FDA nod for Diovan generic

Company will also enjoy 180 days of exclusive marketing rights for the drug in the American market

Sushmi Dey  |  New Delhi 

Ranbaxy Laboratories has received the US Food and Drug Administration (US FDA)'s approval to sell a generic version of Novartis's hypertension medicine Diovan, sources say. The company will enjoy 180 days of exclusive marketing rights for the drug in the American market, it is learnt.

"The company will launch the drug at the earliest," a company executive said, indicating the generic version was likely to enter the American market within the next few days.

The launch of the Diovan generic has been pending since September 2012, when Novartis lost patent protection in this regard. It is expected the launch of the generic will give a significant boost to Ranbaxy's revenue, under pressure for a long time.

In the absence of competition from generics, Novartis clocked about $3.4 billion of sales from this drug globally. Estimates by market analysts show if Ranbaxy launches the drug at a discount of 40-50 per cent, it might earn about $200 million during the six-month exclusivity period.

The US FDA approval marks a positive for Ranbaxy. The company, recently acquired from Japan's Daiichi Sankyo by domestic drug maker Sun Pharmaceutical in a $4-billion transaction, has been in the midst of woes at its largest drug market, the US. Currently, four key Ranbaxy facilities in India are barred from supplying products to the US, owing to violation of manufacturing norms.

Following the untoward developments at its facilities, many of the company's key products awaiting US FDA approval were stuck with the regulator. While Ranbaxy's US-based Ohm Laboratories is allowed to manufacture for that market, sources say it is possible the company has tied up with a third party for sourcing active pharmaceutical ingredient (API), as its primary API plant in Toansa is has been barred from supplying products by US FDA.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, June 27 2014. 00:47 IST